Diasense
This article was originally published in The Gray Sheet
Executive Summary
Expects to gross a maximum of $10.5 mil. from a "best efforts" offering of 3 mil. shares of common stock, according to a prospectus filed with the Securities and Exchange Commission. The proceeds will be used to continue development of its noninvasive glucose sensor systems and for general working capital. Biocontrol Technology, which formed Diasense in 1989 and owns about 44% of its stock, is developing the noninvasive glucose sensor technology under contract with Diasense. In January, BICO submitted a 510(k) to FDA for the Diasensor 1000 ("The Gray Sheet" Jan. 10, In Brief), a production model of the sensor technology. The 510(k) is still under review by the agency
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.